[Subcutaneous implantable cardioverter-defibrillator : Current status and perspectives]

The use of transvenous implantable cardioverter-defibrillators (ICD) for the prevention of sudden cardiac death has been proven in numerous randomized trials. By using a totally subcutaneous ICD (S-ICD) system, it is expected to ensure appropriate protection while avoiding long-term complications associated with transvenous leads, such as systemic infection and electrode dysfunction. Meanwhile, the safety and effectiveness of the S‑ICD has been substantiated by results of large registry studies. Based on the missing option for ventricular stimulation, corresponding recommendations have been integrated into current guidelines for certain patient populations. In the future, the issue of inadequate shocks caused by oversensing may be solved using advanced screening tools and new detection algorithms. Furthermore, a combination of subcutaneous ICD and LCP (leadless cardiac pacer) seems realistic to enable antibradycardia and antitachycardia ventricular pacing.